


# Where Science Becomes Hope

# TRASTUZUMAB: NOT JUST FOR BREAST CANCER ANYMORE

#### SUSAN C. MODESITT, MD, FACOG, FACS

Leach Hendee Professor and Director Gynecologic Oncology Division, GYN/OB Department Gynecologic team leader, Winship Cancer Institute of Emory University Editor-in-Chief, GYNECOLOGIC ONCOLOGY REPORTS








Designated Comprehensive Cancer Center

# DISCLOSURES







- I receive a stipend as EIC of *Gynecologic* Oncology Reports
- I have done one consulting board for Eisai and have received stipends for nonbranded talks for OncLive and Curio sponsored conferences
- Our division has received clinical trial funding support from multiple companies (Ergomed, Gilead, Corcept, Karyopharm, and Mersana)

## ESTRICTED

UNDER 17 REQUIRES ACCOMPANYING PARENT OR ADULT GUARDIAN

#### STRONG LANGUAGE, THOUGHTS AND IDEAS

# **U.S. FEMALE CANCER STATISTICS 2024**

Site	Number	Deaths
Breast	310,720	42,250
Uterus	67,880	13,250
Ovary	19,680	12,740
Cervix	13,820	4,360
Vulva	6,900	1,630

American Cancer Society. Cancer Facts and Figures 2024

# **HER-2 NEU EXPRESSION IN GYNECOLOGIC CANCERS**

# Ovarian Cancer

- Range from 8-66%: estimated at under 25% with HER2 overexpression.
- Endometrial Cancer
  - HER2 overexpression ranges from 14-80% and HER2 gene amplification from 21-47%
  - Uterine papillary serous cancer has 25-30% overexpression
- Cervical Cancer (range from 0-87% depending on study)
  - HER2 overexpression 5.7% in ASCO/CAP compliant studies and 27% in ASCO/CAP non-compliant


Tuefferd M et al. Her2 status in ovarian carcinomas. PLoS One. 2007; 2(11): e1138.

Buza, N. HER2 testing in endometrial serous carcinoma: Time for standardized pathology practice to meet the clinical demand. Arch Pathol Lab Med 145(6):687-91, 2021

Itkin B et al. Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and metaanalysis. PLoS ONE 16(9): e0257976), 2021


# TRASTUZUMAB

- Monoclonal antibody
- Binds to domain IV of the extracellular segment of the HER2 receptor
- Mediates antibody-dependent cellular cytotoxicity (ADCC) by inhibiting proliferation of cells that overexpress HER2




Slide adapted with permission from Dr. Jane Meisel

# WHAT ABOUT DUAL ANTI-HER2 THERAPY?



# **TRASTUZUMAB DERUXTECAN**



### Unique features

- High potency payload
- High drug to antibody ratio (8ish)
- Payload with short systemic half-life
- Tumor selective (cleavable linker)
- Membrane permeable payload

Slide adapted with permission from Dr. Jane Meisel

Chem Pharm Bull (Tokyo). 2019; 67 (3): 173-185. Clin Cancer Res 2016; 22 (20): 5097-5108. Pharmacol Ther. 2018; 181:126-142. Cancer Sci 2016; 107 (7): 1039-1046.

# **TRASTUZUMAB IN GYNECOLOGIC CANCERS**


- Endometrial Cancer
  - Trastuzumab for advanced stage uterine papillary serous cancers
  - NRG-18: Current Phase 3 evaluating trastuzumab in all stages of UPSC
  - Fam-trastuzumab deruxtecan-nxki in recurrent disease (HER2 positive)
- Ovarian Cancer
  - Fam-trastuzumab deruxtecan-nxki in recurrent disease (HER2 positive)

## Cervical Cancer


Fam-trastuzumab deruxtecan-nxki in recurrent disease (HER2 positive)

#### **HISTORY OF MANAGEMENT OF ENDOMETRIAL CANCER:**

#### JOURNEY FROM PROGNOSTIC TO PREDICTIVE MARKERS




## WORSE SURVIVAL OUTCOMES IN HER 2 POSITIVE STAGE 1 UTERINE PAPILLARY SEROUS CARCINOMA




HER2 positive tumors were associated with inferior PFS (aHR 3.50, 95%Cl 1.84-6.67; p < .001) and OS (aHR 2.00, 95%Cl 1.04-3.88; p = .039) compared to HER2-negative tumors even when given Carbo/paclitaxel

# **RANDOMIZED PHASE II TRIAL OF TRASTUZUMAB IN UPSC**



#### WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY



# **ANTIBODY DRUG CONJUGATES APPROVED/USED IN GYN**

- Ovarian Cancer
  - Mirvetuximab
  - Trastuzumab deruxtecan
- Endometrial Cancer
  - Trastuzumab deruxtecan
- Cervical Cancer
  - Tisotumab vedotin
  - Trastuzumab deruxtecan

Two classes of antitumor drugs are commonly used as payloads in ADCs<sup>1</sup>

Microtubule inhibitors <sup>1–5</sup>	DNA-damaging agents <sup>1,2</sup>

Considerations	Targets rapidly proliferating cells	Potent agents that may target DNA independent of cell cycle	
Classes	<ul> <li>Auristatins (eg, MMAE, MMAF)</li> <li>Eribulin</li> <li>Hemiasterlin</li> <li>Maytansinoids (eg, DM1, DM4)</li> <li>Tubulysin</li> </ul>	Calicheamicin     Duocarmycin     Pyrrolobenzodiazenine	
Examples	<ul><li>Mirvetuximab soravtansine</li><li>Tisotumab vedotin</li></ul>	<ul><li>Sacituzumab govitecan</li><li>Trastuzumab deruxtecan</li></ul>	

### FDA approved ADC as of January 2024

Solid tumours		
Trastuzumab emtansine	Anti-HER2 antibody with a DM1 (maytansine derivative) payload and a non-cleavable linker conjugated using lysine–amide coupling with an average DAR of 3.5	HER2' breast cancer (2013)
Enfortumab vedotin	Anti-nectin-4 antibody with an MMAE payload and a cleavable valine- alanine linker conjugated using partial cysteine alkylation with an average DAR of 3.8	Urothelial carcinoma (2019), in combination with pembrolizumab (2023)
Trastuzumab deruxtecan	Anti-HER2 antibody with a DXd (exatecan derivative) payload and a cleavable glycine-glycine-phenylalanine-glycine linker conjugated using full homogeneous cysteine alkylation with an average DAR of 7.7	HER2 <sup>+</sup> breast cancer (2019), HER2 <sup>+</sup> gastric cancer (2021), HER2 <sup>low</sup> breast cancer (2022)
Sacituzumab govitecan	Anti-TROP2 antibody with an SN-38 payload and a cleavable lysine– PAB and carbonate linker conjugated using full homogeneous cysteine alkylation with an average DAR of 7.6	TNBC (2020), urothelial carcinoma (2021), HR+, HER2- breast cancer (2023)
Tisotumab vedotin	Anti-TF antibody with an MMAE payload and a cleavable valine- citrulline linker conjugated using cysteine alkylation (partial) with an average DAR of 4	Cervical cancer (2021)
Mirvetuximab soravtansine	Anti-FRα antibody with a DM4 (maytansine derivative) payload and a cleavable disulfide linker conjugated using lysine-amide coupling with an average DAR of 3.5	FRα <sup>+</sup> ovarian, fallopian tube and peritoneal cancers (2022)

nature reviews clinical oncology https://doi.org/10.1038/s41571-023-00850-2

## **NCCN UTERINE/OVARIAN/CERVICAL CANCER GUIDELINES** 2024

#### SYSTEMIC THERAPY FOR ENDOMETRIAL CARCINOMA

Primary or Adjuvant Therapy (Stage I–IV)				
Chemoradiation Therapy	Systemic Therapy			
Preferred Regimens • Cisplatin plus RT followed by carboplatin/paclitaxel <sup>1,2</sup> <u>Other Recommended Regimens</u> <sup>a</sup> (if cisplatin and carboplatin are unavailable) • Capecitabine/mitomycin <sup>3</sup> • Gemcitabine <sup>4</sup> • Paclitaxel <sup>5,6</sup>	<ul> <li><u>Preferred Regimens</u></li> <li>Carboplatin/paclitaxel<sup>7</sup></li> <li>Carboplatin/paclitaxel/pembrolizumab (for stage III–IV tumors, except for carcinosarcoma) (category 1)<sup>b,c,d,8</sup></li> <li>Carboplatin/paclitaxel/dostarlimab-gxly (for stage III–IV tumors) (category 1)<sup>c,d,e,9</sup></li> <li>Carboplatin/paclitaxel/trastuzumab (for stage III/IV HER2-positive uterine serous carcinoma)<sup>d,f,g,10</sup></li> <li>Carboplatin/paclitaxel/trastuzumab (for stage III/IV HER2-positive carcinosarcoma)</li> </ul>			

#### Useful in Certain Circumstances

- PD-L1–positive tumors
   Nivolumab<sup>f,g,18</sup>
- HER2-positive tumors (IHC 3+ or 2+)
   Fam-trastuzumab deruxtecan-nxki<sup>19</sup>

Original Reports | Gynecologic Cancer

# In the DESTINY-PanTumorO2 Phase II Trial In the DESTINY-PanTumorO2 Phase II Trial

Funda Meric-Bernstam, MD<sup>1</sup> (D); Vicky Makker, MD<sup>2,3</sup> (D); Ana Oaknin, MD<sup>4</sup> (D); Do-Youn Oh, MD<sup>5</sup> (D); Susana Banerjee, PhD<sup>6</sup> (D); Antonio González-Martín, MD<sup>7</sup> (D); Kyung Hae Jung, MD<sup>8</sup> (D); Iwona Ługowska, MD<sup>9</sup>; Luis Manso, MD<sup>10</sup> (D); Aránzazu Manzano, MD<sup>11</sup>; Bohuslav Melichar, MD<sup>12</sup>; Salvatore Siena, MD<sup>13</sup> (D); Daniil Stroyakovskiy, MD<sup>14</sup> (D); Anitra Fielding, MBChB<sup>15</sup>; Yan Ma, MSc<sup>16</sup>; Soham Puvvada, MD<sup>15</sup>; Norah Shire, PhD<sup>15</sup>; and Jung-Yun Lee, MD<sup>17</sup> (D)

DOI https://doi.org/10.1200/JC0.23.02005

Meric-Bernstam, F et al. J Clin Oncol. 2024 Jan 1; 42(1): 47–58.

WINSHIP CANCER INSTITUTE OF EMORY UNIVERSITY


NCI Designated Comprehensive Cancer Center

# In the DESTINY-PanTumor02 Phase II Trial In the DESTINY-PanTumor02 Phase II Trial


Funda Meric-Bernstam, MD<sup>1</sup> (**b**); Vicky Makker, MD<sup>2,3</sup> (**b**); Ana Oaknin, MD<sup>4</sup> (**b**); Do-Youn Oh, MD<sup>5</sup> (**b**); Susana Banerjee, PhD<sup>6</sup> (**b**); Antonio González-Martín, MD<sup>7</sup> (**b**); Kyung Hae Jung, MD<sup>8</sup> (**b**); Iwona Ługowska, MD<sup>9</sup>; Luis Manso, MD<sup>10</sup> (**b**); Aránzazu Manzano, MD<sup>11</sup>; Bohuslav Melichar, MD<sup>12</sup>; Salvatore Siena, MD<sup>13</sup> (**b**); Daniil Stroyakovskiy, MD<sup>14</sup> (**b**); Anitra Fielding, MBChB<sup>15</sup>; Yan Ma, MSc<sup>16</sup>; Soham Puvvada, MD<sup>15</sup>; Norah Shire, PhD<sup>15</sup>; and Jung-Yun Lee, MD<sup>17</sup> (**b**)

DOI https://doi.org/10.1200/JC0.23.02005

- Advanced solid tumors not eligible for curative therapy
- 2L+ patient population
- HER2 expression (IHC 3+ or 2+)
  - Local test or central test by HercepTest if local test not feasible (ASCO/CAP gastric cancer guidelines<sup>1</sup>)<sup>a</sup>
- Prior HER2-targeting therapy allowed
- ECOG/WHO PS 0–1



were to be closed)



#### **Primary endpoint**

 Confirmed ORR (investigator)<sup>c</sup>

#### **Secondary endpoints**


- DOR<sup>c</sup>
- DCR<sup>c</sup>
- PFS<sup>c</sup>
- OS
- Safety

#### Data cut-off for analysis:

• Nov 16, 2022

#### Efficacy

Linca	су	Cervical (n=40)	Endometrial (n=40)	Ovarian (n=40)			ر 100	
Investigator as	ssessment						90 -	
ORR, n (%)		20 (50.0)	23 (57.5)	18 (45.0)	$\left \right $		80 -	
	Complete response	2 (5.0)	7 (17.5)	4 (10.0)		RR, %	70 -	
Best overall	Partial response	18 (45.0)	16 (40.0)	14 (35.0)	Confirmed ORR,	<b>80</b> 60		
response, n (%)	Stable disease	12 (30.0)	13 (32.5)	14 (35.0)		mec	50 -	
11 (70)	PD	7 (17.5)	4 (10.0)	7 (17.5)		nfir	4 untir	40 -
	Not evaluable	1 (2.5)	0	1 (2.5)	-	ပိ	30 -	
DCR <sup>a</sup> at 12 w	eeks, n (%)	27 (67.5)	32 (80.0)	28 (70.0)			20 -	
Median DOR,	months (95% CI)	9.8 (4.2–NE)	NR (9.9–NE)	11.3 (4.1–NE)			10 - 0 -	
Independent o ORR, n (%)	central review:	16 (40.0)	21 (52.5)	17 (42.5)			n	



	All patients (N=99)	IHC 3+ (n=46)	IHC 2+ (n=34)
Median DOR, months (95% CI)	11.8 (9.8–NE)	22.1 (9.3–NE)	9.8 (4.2–12.6)

Analysis of ORR was performed in patients who received ≥1 dose of T-DXd; all patients (n=267; including 67 patients with IHC 1+ [n=25], IHC 0 [n=30], or unknown IHC status [n=12] by central testing) and patients with centrally confirmed HER2 IHC 3+ (n=75) or IHC 2+ (n=125) status. Analysis of DOR was performed in patients with objective response who received ≥1 dose of T-DXd; all patients (n=99; including 19 patients with IHC 1+ [n=6], IHC 0 [n=9], or unknown IHC status [n=4] by central testing) and patients with centrally confirmed HER2 IHC 3+ (n=46) or IHC 2+ (n=34) status. \*Responses in extramammary Paget's disease, head and neck cancer, oropharyngeal neoplasm, and salivary gland cancer. BTC, biliary tract cancer; CI, confidence interval; DOR, duration of response; IHC, immunohistochemistry; NE, non-estimable; ORR, objective response rate.






Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.




Efficacy

#### **TRASTUZUMAB-DERUXTECAN: GYN TUMORS**



NCI Designated Comprehensive Cancer Center

## TOXICITY



# TRASTUZUMAB DERUXTECAN FOR HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-EXPRESSING ADVANCED OR RECURRENT UTERINE CARCINOSARCOMA (NCCH1615): THE STATICE TRIAL

- Phase II trial, patients were classified as HER2-high (IHC 3 or 2+) or HER2-low (IHC 1+) regardless of FISH status.
- The overall response rates in the HER2-high and HER2-low groups were 54.5% and 70.0% respectively
- No difference in duration of response, PFS (6.2 vs. 6.7 months) or OS in the two groups
- Grades 1-2 and 3 pneumonitis/interstitial lung disease occurred in eight (24%) and one (3%) patient, respectively

Nishikawa T et al. JCO 2023 May 20;41(15):2789-2799.

## **DESTINY-02 TOXICITY IN GYN CANCER PATIENTS**


#### TABLE 2. Incidence of Drug-Related Adverse Events

Adverse Event	Endometrial Cancer $(n = 40)$	Cervical Cancer $(n = 40)$	Ovarian Cancer (n = 40)
Drug-related adverse events, No. (%)	36 (90.0)	36 (90.0)	34 (85.0)
Grade ≥3	14 (35.0)	19 (47.5)	21 (52.5)
Serious adverse events	4 (10.0)	3 (7.5)	11 (27.5)
Leading to discontinuation	3 (7.5)	3 (7.5)	1 (2.5)
Leading to dose modification <sup>a</sup>	13 (32.5)	13 (32.5)	18 (45.0)
Associated with death	2 (5.0)	0	0
Most common drug-related adverse events (>10% of total patients), No. (%)			

\*\*\* Interstitial lung disease-10.5%, majority grade 1-2 but three were fatal (one endometrial, one biliary, one other)

Meric-Bernstam, F et al. J Clin Oncol. 2024 Jan 1; 42(1): 47-58.

## **NEW DIRECTIONS TO IMPROVE ADC'S**



DAC, protein degrader–antibody conjugate; FcyR; Fcy receptor; ISAC, immune-stimulating antibody conjugate; NK, natural killer; PDC, probody–drug conjugate; w/o, without

# **QUESTIONS?**

